Johnson & Johnson (NYSE:JNJ) Shares Down 1.1% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares fell 1.1% on Friday. The stock traded as low as $255.12 and last traded at $255.9410. Approximately 10,176,026 shares changed hands during trading, an increase of 27% from the average daily volume of 7,992,505 shares. The stock had previously closed at $258.66.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
• Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
• Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
• Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
• Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, TD Cowen boosted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $275.87.

Johnson & Johnson Stock Down 1.1%

The stock has a market cap of $616.79 billion, a P/E ratio of 29.66, a PEG ratio of 2.60 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm’s 50-day moving average is $266.52 and its two-hundred day moving average is $248.31.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the firm earned $2.77 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Buying and Selling

In related news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last three months. 0.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares during the period. Deutsche Bank AG raised its stake in Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after acquiring an additional 1,376,828 shares in the last quarter. Amundi grew its stake in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, Nuveen LLC increased its holdings in shares of Johnson & Johnson by 6.9% in the fourth quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock worth $2,195,568,000 after acquiring an additional 683,967 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.